Amphastar Pharmaceuticals, Inc. (AMPH): Operating Income
$140.40M
Year ended 2025-12-31
$114.28M
Trailing 12 months to 2026-06-30
+9.3%
3-year compound annual growth
+66.6%
5-year compound annual growth
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $140.40M | -31.7% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $205.42M | +4.3% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $196.99M | +83.2% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $107.50M | +53.8% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $69.89M | +538.0% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $10.95M | n/m | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | -$39.0K | n/m | 2022-03-11, From 2019-01-01 |
| 2018-12-31 | -$8.62M | n/m | 2021-03-15, From 2018-01-01 |
| 2017-12-31 | -$1.27M | n/m | 2020-03-16, From 2017-01-01 |
| 2016-12-31 | $15.38M | n/c | 2019-03-15, From 2016-01-01 |
| 2015-12-31 | -$6.90M | n/m | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | -$17.98M | n/m | 2017-03-15, From 2014-01-01 |
| 2013-12-31 | $17.49M | -31.1% | 2016-03-15, From 2013-01-01 |
| 2012-12-31 | $25.40M | n/a | 2015-03-26, From 2012-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $140.40M | -31.7% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | -$62.28M | n/m |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $19.19M | n/m |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $100.10M | n/m |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $44.80M | -67.3% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $77.22M | n/m |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$535.00M | n/m |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $179.64M | +5.7% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | -$166.76M | n/m |
Compare AMPH, SUPN, PCRX, EBS side by side · Screen every company in Pharmaceutical Preparations ↗